DailyIQ
|
Sector:HealthcareAll sectors
Last updated1 minute ago

ABBV·AbbVie Inc.

$281.94
+7.58 (+2.76%)
High
$282.13
Open
$277.00
Market Cap
496.77B
52W High
$283.43
Low
$274.74
P. Close
$281.94
P/E
78.73
52W Low
$187.00
Fwd P/E
16.92
DailyIQ Est.
$295.59
Inst. Ownership
37.8%
Short Interest
0.90%
Days to Cover
4.1
Div. Yield
2.51%
Last Ex-Div
Jul 15, 2026
Div. Growth
12+ yrs
NewEarnings release, scored · filed Jul 31, 2026Guidance lowered · 103 lines scoredSee the breakdown
Technical Score (1D)
55
BULLISH
News Sentiment
59
BULLISH
On Oct 13, AbbVie released new Phase 3 AFFIRM data showing that subcutaneous SKYRIZI achieved higher rates of endoscopic remission and ulcer‑free endoscopy compared with placebo in patients with moderately to severely active Crohn's disease. The study confirmed superiority in the co‑primary endpoints of clinical remission and endoscopic response at week 12, reinforcing SKYRIZI’s efficacy profile. These results support AbbVie’s application to the U.S. Food and Drug Administration for a subcutaneous induction dosing regimen, potentially expanding SKYRIZI’s market reach and providing a new therapeutic option for Crohn's patients. On the same day, a comparison article discussed AbbVie’s strategic shift from reliance on a single blockbuster drug toward immunology, oncology, and neuroscience therapies, noting that the company is diversifying beyond its traditional portfolio. The piece highlighted that AbbVie’s U.S. sales are heavily dependent on three major wholesalers, while Novo Nordisk focuses on metabolic health and obesity treatments. Both articles emphasized the companies’ strategic risk and reward profiles rather than immediate financial metrics.
LOW TARGET
$200 -29.1%
1 analysts
MEAN TARGET
$283 +0.2%
23 analysts
HIGH TARGET
$328 +16.3%
17 analysts
PRICE RANGE
$200.00 - $328.00
SB / B / H / S / SS
10/22/7/1/1
DAILYIQ EST.
$295.59 (+4.8%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYQ
Country
United States
Website
abbvie.com
Symbol
ABBV
Description
AbbVie is a global biopharmaceutical company focused on discovering and delivering innovative medicines. The company's core business centers on developing and commercializing a diverse portfolio of therapies, including treatments for autoimmune diseases like Humira and Skyrizi, and oncology drugs such as Imbruvica and Venclexta/Venclyxto. AbbVie also provides solutions for neuroscience conditions, encompassing treatments for schizophrenia, migraine, and Parkinson's disease. Furthermore, the company's offerings extend to eye care products and therapies for chronic hepatitis C virus infection and gastrointestinal disorders. Headquartered in North Chicago, Illinois, AbbVie's research-driven approach aims to address significant unmet medical needs across various therapeutic areas.
Bought (1Y)
0 shares
$0
Sold (1Y)
32,710 shares
$8.2M
RAPP EDWARD J-
Award/Grant129 shares2026-09-30
Quaggin Susan E-
Award/Grant59 shares2026-09-30
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER
Option Exercise32,710 shares2026-08-14
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER
Sell32,710 shares2026-08-14
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER
Option Exercise32,710 shares2026-08-14
View full insider trading history →
60/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
70.2%
Net Margin
6.9%
Revenue CAGR
9.4%
Current Ratio
0.67x
Debt / Equity
-20.49x
Return on Equity
-129.2%
View full financials →
Earnings Summary
...

EPS

EstBeatMiss
$1.48$2.14$2.79$3.44$4.09Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.79 - -
Q2'26$3.68$3.65-0.7%
Q1'26$3.74$2.65-29.2%
Q4'25$2.71$2.71+0.2%
Q3'25$1.78$1.86+4.2%
Q2'25$2.91$2.97+2.1%

Revenue

EstBeatMiss
$14.6B$15.5B$16.3B$17.2B$18.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$17.7B - -
Q2'26$17.1B$17.0B-0.6%
Q1'26$16.8B$15.0B-10.7%
Q4'25$16.7B$16.6B-0.8%
Q3'25 - $15.8B -
Q2'25 - $15.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABBV Stock Snapshot

NEUTRAL55/100
$281.94+$7.58 (2.8%)
Market cap
496.77B
P/E ratio
78.7
Day range
$274.74 – $282.13
News sentiment
59/100 · Neutral
Analyst target
$282.61 (+0.2%)
Consensus
Buy · 41 analysts
52-week range+50.8% off low · -0.5% from high
$187.00$283.43
Price $281.94 DailyIQ Est. $295.59

ABBV ranks mid-pack on momentum, neither leading nor lagging its peers by much. A stock this widely held moves on consensus revisions more than on individual catalysts.

Reverse DCF

What growth is priced into ABBV?

FAIR

At today's price, AbbVie Inc. needs to grow free cash flow about 10.9% a year for the next 10 years to justify its valuation at a 7.24% cost of capital. Over its actual history it has compounded free cash flow at 13.3% a year, so the market is asking for 2.4 percentage points below its own delivered rate. On that basis ABBV looks priced roughly in line with its own growth record.

Implied FCF growth
10.9%
Historical FCF CAGR
13.3%
Growth gap
-2.4 pts
Verdict
FAIR
Discount rate (WACC)
7.24%
Beta
0.52

Behaviour On Record

What ABBV's own history says about today's numbers

Realized volatility (21d)
15.8% 20th pct
Below its peak
-2.3%
vs 200-day average
+17.8%
Up days (1y)
49%

AbbVie Inc. is currently running 15.8% annualised volatility over the last 21 sessions. Measured against ABBV's own 13 years of daily returns rather than a market-wide average, that is the 20th percentile — unusually subdued by its own history, against a typical reading of 21.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ABBV is trading -2.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -20.9%, and the deepest was -36.0% in 2018. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +17.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 90th percentile — a wider gap than this stock usually carries. Over the past year ABBV closed higher on 49% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, ABBV finished the month higher 8 of 14 times, with a median return of +4.1% and an average of +0.2%. Its strongest month historically has been November at +5.0% on average, its weakest January at -2.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ABBV has opened more than 2% away from the prior close in 41 of 3,267 sessions (1.3% of the time), with the largest gaps running +6.3% and -4.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ABBV moved an average of 2.9% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.7% and a largest of +4.6%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against ABBV's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ABBV's sector?

AbbVie Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#3 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for ABBV?

CallsPuts

For AbbVie Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.58), with at-the-money implied volatility around 3.1%. The options market is pricing roughly a ±0.2% move by that expiry — a range of about $276.20–$277.48.

Put/call ratio (2026-10-16)
0.58
ATM implied volatility
3.1%
Total open interest
28,402
Expected move by 2026-10-16
±0.2% ($276.20–$277.48)

Analyst Rating Changes

Are analysts turning bullish or bearish on ABBV?

RBC Capital most recently reiterated its rating on AbbVie Inc. to Outperform on Oct 13, 2026 with a price target of $280. Over the last 90 days, coverage has run 2 upgrades against 0 downgrades, a net bullish lean.

Latest action
RBC Capital — Outperform
90-day upgrades
2
90-day downgrades
0
Net rating momentum
+2
DateFirmActionRatingPrice target
Oct 13, 2026RBC CapitalReiteratedOutperform$280
Oct 9, 2026UBSMaintainedNeutral$260 → $275
Oct 9, 2026GuggenheimReiteratedBuy$288
Oct 8, 2026JP MorganMaintainedOverweight$285 → $300
Oct 8, 2026Cantor FitzgeraldMaintainedOverweight$285 → $290
Oct 7, 2026Morgan StanleyMaintainedOverweight$296 → $310
Oct 6, 2026ScotiabankMaintainedSector Outperform$280 → $320
Sep 10, 2026HSBCMaintainedBuy$300 → $315
Aug 20, 2026Piper SandlerMaintainedOverweight$298 → $303
Aug 17, 2026Wells FargoMaintainedOverweight$295 → $300
Aug 13, 2026Wolfe ResearchUpgradePeer Perform → Outperform$300
Aug 11, 2026BNP ParibasMaintainedNeutral$218 → $247

Earnings Release, Scored

What did AbbVie Inc.'s latest earnings release say?

Filed Jul 31, 2026 · SEC Form 8-K, Exhibit 99

Guidance lowered
Tone67.3/ 100
Hedging words0.13per 100 words

Most important lines

  1. 1

    Worldwide net revenues were $16.990 billion, an increase of 10.2 percent on a reported basis, or 9.5 percent on an operational basis.

  2. 2

    Global Skyrizi net revenues were $5.505 billion, an increase of 24.4 percent on a reported basis, or 24.0 percent on an operational basis.

  3. 3

    Global Rinvoq net revenues were $2.525 billion, an increase of 24.5 percent on a reported basis, or 23.7 percent on an operational basis.

Scores describe the release's wording. They are not a forecast.

Read all 103 scored lines →

Peers & ETF holders

ABBV peers & ETF holders

Drug Manufacturers - GeneralMarket cap · today

Top ETF holdersWeight

News Sentiment Analysis

Sentiment gathered from recent headlines

59/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
The article compares AbbVie (ABBV) and Novo Nordisk (NVO) as potential 2026 investments, highlighting each company’s strategic focus and market positioning. AbbVie is shifting from a single blockbuster dependency toward immunology, oncology, and neuroscience, while Novo Nordisk concentrates on metabolic health and obesity treatments. Both firms face patent cliffs and revenue concentration risks, but their growth prospects differ, with AbbVie pursuing diversified therapeutic areas and Novo Nordisk benefiting from a booming obesity market. The piece evaluates financial metrics and competitive dynamics, offering a balanced view of each company’s risk‑reward profile.
What did this article say?
AbbVie released new Phase 3 AFFIRM data on October 13, 2026, showing that subcutaneous SKYRIZI achieved higher rates of endoscopic remission and ulcer‑free endoscopy compared with placebo in patients with moderately to severely active Crohn's disease. The study confirmed superiority in co‑primary endpoints of clinical remission and endoscopic response at week 12, reinforcing the drug’s efficacy profile. These results support AbbVie's application to the U.S. Food and Drug Administration for a subcutaneous induction dosing regimen, potentially expanding SKYRIZI’s market reach and providing a new therapeutic option for Crohn's patients.
What did this article say?
AbbVie presented 22 scientific abstracts at the American College of Gastroenterology 2026 Annual Scientific Meeting, highlighting new data for its inflammatory bowel disease portfolio. The company unveiled AFFIRM results demonstrating efficacy of SKYRIZI® (risankizumab-rzaa) in advanced therapy‑naïve Crohn’s disease patients. Open‑label extension analyses showed sustained long‑term outcomes with SKYRIZI and RINVOQ® (upadacitinib). These findings reinforce AbbVie’s leadership position in IBD treatment and support continued growth prospects for its specialty drug pipeline.
What did this article say?
AbbVie’s dividend yield has slipped to about 2.6%, the lowest level since early 2018, as the share price has risen faster than the dividend. The company has maintained a steady record of dividend increases inherited from Abbott, keeping its payout growth consistent. Despite the lower yield, analysts argue that AbbVie remains a solid income play due to its dividend‑king status and stable cash flow. The decline reflects a broader market trend of share price appreciation outpacing dividend growth rather than a dividend cut.
What did this article say?
AbbVie (ABBV) secured FDA Breakthrough Therapy Designations for its experimental antibody drug conjugate telisotuzumab adizutecan in colorectal and non‑small cell lung cancer, targeting biomarker‑defined patient groups. The designations signal accelerated development and potential market advantage for these solid‑tumor indications, bolstering AbbVie’s oncology pipeline. The move highlights the company’s focus on antibody‑drug conjugates and may enhance investor confidence in its cancer drug strategy, though it remains one of several factors influencing the firm’s overall risk profile.
What did this article say?
AbbVie delivered an average annual return of 20.55% over the past five years, outperforming the market by 8.13% on an annualized basis. The company’s market capitalization stood at $481.85 billion as of the report. The performance highlights the company’s strong revenue growth and successful product pipeline. Investors noted the sustained profitability and robust dividend policy as key drivers of the outperformance. The data underscores AbbVie’s resilience amid competitive pressures in the biopharmaceutical sector.
What did this article say?
UBS increased its price target for AbbVie from $260 to $275 while maintaining a neutral rating. The move reflects confidence in the company’s earnings outlook and product pipeline. The new target aligns with the average market consensus of $284.04. This adjustment signals a modest bullish view but does not represent a significant shift in analyst sentiment.
What did this article say?
AbbVie reported a 10.2% rise in total revenue to $16.99 billion despite Humira sales falling 35.9% to $756 million. The company’s immunology portfolio, led by Skyrizi and Rinvoq, generated $8.786 billion in the quarter, up 24.4% and 24.5% respectively. These gains demonstrate AbbVie’s successful replacement strategy for its flagship drug, supporting a positive outlook for future growth.
What did this article say?
BofA Securities increased its price target for AbbVie from $289 to $305, signaling a more optimistic view of the company’s future earnings. The upgrade reflects confidence in AbbVie's pipeline and its ability to generate steady cash flow. The higher target suggests that analysts expect AbbVie to outperform market expectations in the coming quarters.
What did this article say?
Cantor Fitzgerald increased AbbVie's price target to $290 from $285, reflecting a positive outlook for the company. The firm maintained an Overweight rating for AbbVie, indicating strong conviction in near‑term upside. The target lift aligns with broader optimism for AbbVie's growth prospects amid mixed industry outlooks. The adjustment suggests analysts expect the company to outperform peers in the coming period.

Technical Analysis

Real-time indicators across multiple timeframes

55
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $165.57B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy180,779,69910.00%$41.31B2026-01-29
BlackRock, Inc.▼ Sell149,488,4128.27%$37.62B2026-08-07
JPMorgan Chase & Co▼ Sell47,862,7962.65%$12.17B2026-08-12
Geode Capital Management, LLC▲ Buy46,998,4332.60%$11.81B2026-08-12
Morgan Stanley▲ Buy38,901,0012.15%$9.79B2026-08-13
Capital Research Global Investors▼ Sell30,101,5511.66%$7.57B2026-08-12
Norges Bank▼ Sell25,554,5381.41%$6.43B2026-08-12
Bank of America Corp▼ Sell21,237,7641.17%$5.34B2026-08-14
FMR LLC (Fidelity)▼ Sell20,773,7861.15%$5.23B2026-08-13
Northern Trust Corp▼ Sell20,558,4471.14%$5.17B2026-08-13
Capital World Investors▲ Buy19,178,9661.06%$4.83B2026-08-12
Goldman Sachs Group Inc▲ Buy16,291,6300.90%$4.10B2026-08-14
Fisher Asset Management, LLC▲ Buy9,497,9700.53%$2.39B2026-08-04
Wells Fargo & Company▲ Buy9,017,5800.50%$2.27B2026-08-14
Invesco Ltd.▼ Sell7,114,7820.39%$1.79B2026-08-14
Janus Henderson Group plc▲ Buy6,931,0360.38%$1.51B2026-05-18
Wellington Management Group LLP▼ Sell5,055,5890.28%$1.27B2026-08-14
AllianceBernstein L.P.▼ Sell4,092,3350.23%$890.04M2026-08-14
Citadel Advisors LLC▲ Buy3,169,7830.18%$797.64M2026-09-02
Marshall Wace, LLP▲ Buy2,990,5120.17%$752.53M2026-08-13
Citigroup Inc▲ Buy2,327,2070.13%$585.62M2026-08-03
D. E. Shaw & Co., Inc.▲ Buy2,102,3160.12%$529.03M2026-08-14
AQR Capital Management LLC▲ Buy2,015,2380.11%$507.11M2026-08-14
Prudential Financial Inc▲ Buy1,904,9970.11%$479.37M2026-08-12
Man Group plc▼ Sell1,704,0160.09%$428.80M2026-08-14
Q2 2026 flow:14.71M sh bought ($3.70B)19.62M sh sold ($4.91B)net -4.91M sh (−$1.21B)
View full institutional holdings history →
Congressional Trading Activity
25 disclosed trades · ~$316.0K est. traded value · 10 buys, 15 sells
MemberChamberStateTypeAmountTradedFiled
Pete SessionsHouseTX17▼ Sell$15K - $50K2026-09-142026-09-18
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2026-05-052026-06-03
Alan ArmstrongSenateOK▲ Buy$15K - $50K2026-03-272026-07-21
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-12-082026-01-13
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
John BoozmanSenateAR▼ Sell$1K - $15K2025-08-222025-09-12
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-08-142025-09-11
John BoozmanSenateAR▼ Sell$1K - $15K2025-08-112025-09-12
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-08-042025-08-15
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-222025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-222025-08-13
Ritchie John TorresHouseNY15▼ Sell$1K - $15K2025-07-112025-08-20
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-172025-08-13
Josh GottheimerHouseNJ05▲ Buy$1K - $15K2025-05-222025-06-11
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-05-052025-05-06
Julia LetlowHouseLA05▲ Buy$1K - $15K2025-04-282026-01-13
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-04-172025-05-14
Jefferson ShreveHouseIN06▼ Sell$50K - $100K2025-04-172025-05-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-04-072025-05-09
View full congressional trading history →

Discover More

GILD
Gilead Sciences, Inc.
$150.96
+2.06%
ARGX
Argenx SE American Depositary Shares
$834.72
+4.00%
DGRO
iShares Core Dividend Growth ETF
$77.51
-0.09%
MDGL
Madrigal Pharmaceuticals Inc.
$460.18
+1.78%
AXSM
Axsome Therapeutics Inc.
$163.15
+4.37%
RHHBY
Roche Holding AG
$55.06
+2.40%
XLV
Health Care Select Sector SPDR Fund
$172.87
+1.89%
KYMR
Kymera Therapeutics Inc.
$107.99
+1.23%
EXEL
Exelixis Inc.
$61.03
+2.55%
BIIB
Biogen Inc.
$233.34
+1.94%